SPECIAL REPORT: Riding the Biotech Economic Tsunami - Surfing to Safety or Wipeout?

Table of Contents

• Executive Summary
  • Strategic Considerations
  • Stakeholder Implications
• Overview.
• Public and Private Equity Financing
  • The IPO Downturn
  • VC Investment
    • Platform-Technology-Derived Therapeutic Companies
    • Therapeutic Platform Companies
    • Target-Based Therapeutic Companies
    • Increasing Trend Toward Research-Stage Development Programs
• Mergers and Acquisitions
  • Products and Pipelines as Drivers for M&A
  • Platform Technologies as Drivers for M&A
• Corporate Partnerships
  • Deal Structure and Assessing Deal Value
  • Target and Lead Discovery
  • Target Identification and Validation Deals
  • Target Identification and Drug Discovery Through Academic Alliances
  • Lead Discovery Deals
  • Lead Identification Deals
    • Target-Focused Screening
    • Library- and Chemistry-Focused Screening
  • Lead Optimization Deals
    • Medicinal and Fragment-Based Screening
    • Drug Delivery
    • Drug Profiling
  • Protein Optimization Deals
  • Molecular Diagnostics Deals
  • Therapeutic Platforms Deals
    • Protein Therapeutics and Monoclonal Antibodies
    • Nucleic-Acid-Based Therapeutics
    • Cell Therapy
• Outlook for Biotech Investment and Trends

Tables

• 1. Biotechnology Initial Public Offerings, 2008
• 2. Blockbuster and Top-Selling Drugs Acquired Through Pharma-Biotech Acquisitions
• 3. Blockbuster and Top-Selling Drugs Acquired Through Biotech-Biotech Acquisitions
• 4. Select Target Discovery Corporate Partnerships, 2008
• 5. Select Academic Drug Discovery and Research Alliances, 2008
• 6. Select Lead Identification Corporate Partnerships, 2008
• 7. Select Lead Optimization Corporate Partnerships, 2008
• 8. Select Protein Optimization Corporate Partnerships, 2008
• 9. Select Molecular Diagnostics Partnerships, 2008
• 10. Select Therapeutic Platform Corporate Partnerships, 2008

Figures

• 1. Biotech Quarterly Initial Public Offerings and Venture Capital Investments, 2002-2008
• 2. Life-Sciences-Related Venture Capital Investments, 2008
• 3. Technology Focus of Biotech Series A Companies, 2008
• 4. Developmental Stage of Therapeutic Biotech Companies with Series A Investments, 2005 and 2008
• 5. Biotechnology M&As Worth More Than $100 Million, 2002-2008